US FDA Says Shortage of Novo's Weight-Loss Drug Resolved
(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ) that's also probably bad news for Hims & Hers Health ( HIMS -17.80%).
Giftify (GIFT) announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback